SEC Filing | Harvard Bioscience, Inc.

View:

Download DOC

Download PDF

Download XLS

Form 8-K Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 14, 2013

HARVARD BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Delaware	001-33957	04-3306140
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

84 October Hill Road, Holliston, MA	01746
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (508) 893-8999

________________________________________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
	[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 14, 2013, Chane Graziano retired and resigned as Chief Executive Officer of Harvard Bioscience, Inc. (the "Corporation"), and as a member of the Corporation's Board of Directors (the "Board"). Mr. Graziano has not expressed any disagreement with the Corporation on any matter relating to the Corporation's operations, policies or practices. The Board will immediately commence a search to hire a permanent Chief Executive Officer.

Effective as of May 14, 2013, the Board appointed David Green, the current President of the Corporation, to serve as the Interim Chief Executive Officer of the Corporation. Mr. Green has served as the Corporation's President and a member of the Board of Directors of the Company since March 1996.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1

Harvard Bioscience Inc. press release, dated May 15, 2013

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		HARVARD BIOSCIENCE, INC. (Registrant)
May 14, 2013 (Date)		/s/ THOMAS MCNAUGHTON Thomas McNaughton Chief Financial Officer & Principal Accounting Officer

EXHIBIT INDEX

Exhibit 99.1

Harvard Bioscience Inc. press release, dated May 15, 2013

Harvard Bioscience Announces Retirement of CEO and Appointment of Interim CEO

EXHIBIT 99.1

Harvard Bioscience Announces Retirement of CEO and Appointment of Interim CEO

HOLLISTON, Mass., May 15, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its Board of Directors has appointed David Green, the Company's President and member of the Board since 1996, as interim Chief Executive Officer following the retirement and resignation of Chane Graziano as Chief Executive Officer and a Director of the Company.

Mr. Graziano commented, "I would like to thank all of the Harvard Bioscience employees worldwide for their commitment and service to the Company over the past 17 years. We have accomplished a great deal together. I have chosen to resign today for personal reasons. We are well on our way in the process of separating Harvard Apparatus Regenerative Technology from Harvard Bioscience which will unlock significant shareholder value as HART achieves its milestones, and HBIO once again becomes active in acquiring complementary product lines or companies. At 74 years of age, 17 years as CEO of HBIO, and 49 years in the industry, it is the right time for me to retire."

The Board of Directors will immediately commence a search to hire a new Chief Executive Officer.

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. Our products are sold to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426

CONTACT: David Green
         President and Interim CEO
         dgreen@harvardbioscience.com
         Tel: 508 893 8999
         Fax: 508 892 6135

         Tom McNaughton
         CFO
         tmcnaughton@harvardbioscience.com